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INSULIN secreting tumours producing inappropriate hyperinsulinism are rare.
Wilder, Allen, Power and Robertson, in 1927 described the first patient in whom
hypoglycaemia was shown to be related to carcinoma of the pancreatic islets,
which were presumed to be secreting insulin. The majority of insulinomas are
small benign tumours amenable to surgical removal. They cause severe metabolic
and/or behavioural upset and are not always correctly diagnosed. Successful
treatment depends upon clinical awareness, accurate biochemical diagnosis,
radiological localization and precise surgical removal. Some tumours are malig-
nant 1, 2 and these tend to metastasize to regional lymph nodes and the liver. Like
other polypeptide-secreting carcinomas they are usually relatively slow growing,
the hypoglycaemia tending to be more devastating than the catabolic effects of
the metastases.
We report the experience of insulin secreting islet cell tumours at the Royal
Victoria Hospital, Belfast. Sixteen cases have been treated between 1960 and
1980, 3 of which were malignant. These were, we believe, the only insulinomas
associated with hypoglycaemia diagnosed in Northern Ireland (population 1.5
million) during the past 20 years so that the incidence was approximately 0.5 per
million per year. The aim of this paper is to demonstrate the changes in diagnostic
techniques which have evolved during the past 20 years, and to assess their value.
CLINICAL FEATURES
Ten patients were male and six female, with ages ranging from 18 to 74 years.
Their symptoms at the time of presentation were varied and often bizarre with
neurological and behavioural disorders predominating. Nine patients developed
unusual behaviour patterns with psychological disturbances; 13 patients reported
neurological symptoms including loss of consciousness, transient hemiparesis,
epileptiform attacks, double vision, dizziness, staggering and/or numbness. Other
complaints were of headaches and attacks of sweating, hunger or vomiting.
21Perhaps the most spectacular complaint was from a patient (MR) who stated
that she "woke up unconscious". This was her way of stating that people had
difficulty rousing her each morning. Another patient (ET) lost consciousness in
a golf bunker after numerous energetic attempts to remove his ball. One young
man (HS) habitually went to his work as a labourer after eating a minimal break-
fast - on a number of occasions while cycling home for lunch he collapsed and
lost consciousness at the roadside. One adult man (JH) had been admitted to a
mental hospital because of bizarre and inappropriate behaviour, culminating in
an episode of "indecent exposure" when he went to the front door to collect the
milk bottles on a Sunday morning before breakfast, without his trousers.
Two patients presented with weight loss (one of these was subsequently shown
to have a malignant tumour); in contrast many of the others had gained weight.
This may have been as a result of the anabolic effect of insulin or, alternatively,
because the patients discovered that repeated carbohydrate intake modified their
symptoms. Another patient, (LM) a diabetic on insulin treatment, had been found
to require less and less insulin and was finally able to stop his insulin therapy
entirely, before laparotomy for symptoms of intestinal obstruction revealed an
insulin secreting pancreatic islet-cell tumour.
DIAGNOSIS
The initial suspicion that symptoms may be due to hypoglycaemia is the
essential part of the diagnostic process, and was made by doctors from various
disciplines. The suspicion was raised for six patients by a neurologist, in one by a
psychiatrist, in two by general physicians and in the remainder by their family
doctors. In all instances the triad was demonstrated of (1) symptoms compatible
with hypoglycaemia, (2) a demonstrably low blood sugar, and (3) relief of the
symptoms by taking glucose.
Confirmation of the suspicion requires biochemical and radiological investiga-
tion. Diagnostic tests during the past 20 years have included early morning fasting
estimations of plasma glucose, prolonged fasting, an extended 50G oral glucose
tolerance test and a l.OG tolbutamide tolerance test. In twelve cases measurement
of fasting p!asma insulin by radioimmunoassay 4 was possible (normal fasting
range 5-15 mU/1). The results of these tests are summarized in Tables I and II.
Early morning fasting plasma glucose was 2.2 mmol/l (40 mg/l00 ml) or less
in 13 of the 16 patients: in 10 of the 11 cases where plasma insulin measurements
were possible it was above 15 mU/I, and even the figure of 13 mU/1 in Case 15
is inappropriately high for the very low blood sugar of 1.5 mmol/1.
While fasting under supervision, all patients became hypoglycaemic. Only 4
patients required to fast more than 12 hours, the one who persisted up to 36 hours
before demonstrating hypoglycaemia had the smallest adenoma in this series
22TABLE I
Plasma Glucose and Insulin Data during fasting
Lowest early
morning values of
plasma glucose and
corresponding
plasma insulin
Lowest plasma glucose
during prolonged fast
and corresponding
plasma insulin
Year of Glucose
Sex operation (mmoil/l)
M
F
M
F
M
M
F
M
M
F
M
M
M
M
F
F
1960
1964
1964
1965
1966
1967
1969
1972
1972
1973
1975
1975
1976
1976
1978
1978
4.0
2.0
0.8
1.3
1.4
1.1
2.2
1.1
1.5
2.2
2.2
3.3
2.8
1.2
1.5
0.8
Insulin Glucose
(mu/1) (inunol/l)
41*
240
75
20
36
18
16
100
125
116
13
41
1.8
1.1
1.4
1.5
1.5
1.1
2.2
1.8
1.4
1.9
1.5
2.0
1.1
3.1
2.5
1.3
Insulin time of
(mu/I) fasting
(hr)
41*
240
75
29
36
21
23
23
165
64
30
8.0
15.5
12.0
7.0
12.0
14.0
10.6
10.5
6.0
6.0
24.0
36.0
10.5
10.0
10.2
Footnote:
* plasma insulin measured
immunoassay and reported
by Dr. C. N. Hales, Cambridge, by an early radio-
to be "elevated".
(case 13). At least 4 patients became spontaneously hypoglycaemic during the
night, and formal fasting was unnecessary - the problem was more one of
clinical management with intravenous glucose infusions prior to surgery.
Fifteen of the patients were studied during an oral GTT, which was extended
beyond 2 hours in 9 instances. The shape of the glucose curve was not informative:
plasma glucose values were usually low throughout, with a very minor rise after
the 5OG glucose load. Two patients showed plasma glucose well into the diabetic
range case 7 was not known to be diabetic and had normal blood glucose
values post-operatively. Case 14 was an insulin requiring diabetic before develop-
ing his islet cell carcinoma and has been recorded elsewhere 6. The time of onset
of hypoglycaemia after the peak of the curve was variable (up to 9 hours) and
some patients were not followed sufficiently long to achieve hypoglycaemia. Only
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Case
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Age
38
39
66
41
43
45
74
51
35
57
19
68
31
49
18
57
M.O'N
H.P.
W.B.
R.McC
H.S.
L.I'A
M.R.
J.H.
J.M.
M.S.
E.T.
J.D.
A.S.
L.M.
L.McL
S.McGTABLE II
Plasma Glucose and Insulin Data during Oral Glucose Tolerance Test,
and I/V Tolbutamide Test.
Lowest plasma glucose
following the peak
of 50 g OGIT and
corresponding plasma
insulin
1960
1964
1964
1965
1966
1967
1969
1972
1972
1973
1975
1975
1976
1976
1978
1978
1.4
1.6
1.8
1.6
6.7
1.1
11.2
1.9
1.9
4.5
1.9*
1.2
8.2
2.2
2.0
* glucose and insulin values observed
standard OGTT.
195
32
27
46*
99
210
33
76
time
from
Oral
Glucose
(hr)
9.0
3.0
4.5
3.5
2.0
4.0
2.0
3.5
4.0
2.0
2.5
0.5
2.0
2.0
5.5
Lowest plasma glucose
following 1.0 g tolbuta-
mide I/V and
corresponding plasma
insulin
Glucose Insulin
(mmol/I) (mu/I)
1.1
1.1
1.5
1.9
1.4
1.4
200
28
time from
I/V tol-
butamide
(hr)
0.25
2.0
0.5
0.5
0.5
0.5
following a mixed meal, rather than
four patients, including the two diabetics, did not produce a plasma glucose of
2.2 mmol/l or less during this test. In all cases where plasma insulin was measured
it was clearly inappropriately elevated.
The I/V tolbutamide test was used prior to the introduction of insulin radio-
immunoassay but only occasionally after 1965. Hypoglycaemia was certainly
demonstrated rapidly in all six patients, but the levels of plasma glucose were not
markedly lower than those achieved by simple fasting, and the test is not used
routinely at present.
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Case
Year of Glucose Insulin
Age Sex operation (mmol/l) (mu/i)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
M.O'N
H.P.
W.B.
R.McC
H.S.
L.I'A
M.R.
J.H.
J.M.
M.S.
E.T.
J.D.
A.S.
L.M.
L.McL
S.McG
38
39
66
41
43
45
74
51
35
57
19
68
31
49
18
57
M
F
M
F
M
M
F
M
M
F
M
M
M
M
F
F
Footnote:RADIOLOGY
Arteriography
Comparison of the arteriographic, operative and histological findings is made
in Table III. Except in one patient (case 6) radiology was performed by the same
radiologist (E McI). The main investigation used to localize the tumour was
coeliac axis angiography by retrograde femoral artery catheterization. The
examination was carried out under local anaesthesia with mild pre-medication.
Hyoscine-N-butylbromide was used to prevent movement of bowel gas between
the series. A standard 7-gauge polyethylene catheter, pre-curved for injection, was
used. The technique required a rapid film-changer. Initially the coeliac axis was
examined by hand injection of 15-20 mis Triosil 440. Films were taken for 15
seconds with emphasis on films in the capillary phase. These films were inspected
and decision made on further views (either lateral or oblique with caudal or
cephalad angulation, or superior mesenteric injection for super-selective catheter-
isation). Subtraction techniques were used for the examination of films.
Ultrasound Examination
A Picker Echoview with a 2.5 MH long focus transducer was used. Scans
were obtained in longitudinal, transverse and oblique projections.
Computerized Axial Tomography
This was performed at 1.5 cm intervals through the pancreas. The equipment
used was an EMI 5005/2085 scanner with a field of thirteen inches and a scanning
time of 25 seconds. Scans were also obtained after enhancement with 50 mIs
Urografin 370. A further series of scans was then obtained during simultaneous
enhancement with 25 mls Urografin 370 injected at I ml par second during each
scan cycle.
The results of the radiological findings and their correlation with the surgical
findings are listed in Table III. The only case of false-negative arteriography, (case
6) was investigated elsewhere; in all the remaining cases arteriography was useful
in predicting tumour site. Benign insulinomas varied in size from one to several
centimetres in diameter. They were well demarcated and showed a dense capillary
blush. In contrast, the malignant tumours were poorly demarcated, had poor
capillary blush and showed end-arterial distortion and neovascularity.
Ultrasonic examination demonstrated only tumours in excess of 3 cm. in
diameter. It proved much more valuable in the head than in the body or tail
of the pancreas. Computerized axial tomography appears promising particularly
when simultaneous enhancement was employed.
These methods are illustrated in the figure.
SURGERY
Wide exposure of the whole pancreas was usually achieved by a long transverse
epigastric incision. In six patients the tumour was in the head of the pancreas:
these were locally resected without mortality but with considerable short-term
25TABLE III
Radiological and Operative Findings
(All cases were islet cell adenomas except 6, 14 and 16 which were carcinomas).
Case
1
2
4
5
6
7
8
9
10
11
12
13
Coeliac Angiogram
Not done
Not done
Not done
Not done
Not done
Normal (radiology elsewhere)
Not done
Increased vascularity of head of
pancreas
2 cm tumour in body
Capillary blush probably in head of
pancreas
Single tumour in extreme tail of
pancreas
4.0 cm diameter tumour in head of
pancreas
Small tumour to left of coeliac axis
14 Large tumour extending from spine to
splenic pedicle - 8 x 7 cm
15 3 tumours. upper head, high neck and
extreme end of tail of pancreas
(C.A.T. Scan: Abnormal thickening
junction of body and tail of pancreas
16 Single large tumour in upper quadrant
of head: ? another in neck of pancreas
(C.A.T. Scan: Single tumour in head
of pancreas
Operative Findings
1.0 cm diameter tumour at junction of head/
neck of pancreas
1.0 cm diameter tumour at head of pancreas
1.0 cm diameter tumour
1.2 cm diameter tumour at junction of head
and uncinate process
2.0 cm diameter tumour at junction of head
and uncinate process
Two large modules in pancreas
1.0 cm diameter tumour at head of pancreas
Large tumour upper/lateral area of head of
pancreas
Tumour deep in upper part of head of
pancreas
1.0 cm diameter tumour to left of neck of
pancreas
2.0 cm diameter tumour in tail of pancreas
Spherical tumour in head of pancreas
No macroscopic tumour. Microscopic
adenoma found after subtotal distal
pancreatectomy
Tumour of body/tail of pancreas 9 x 9 cm
3 tumours.
0.7 cm in neck
2.0 cm mid-body
2.0 cm extreme tail
Massive tumour in head of pancreas. and
multiple hepatic metastases
26FIG. 1.
ULTRASOUND
The upper two secti-ns show a large (3 cm.) insulinoma in the head of the
pancreas - demonstrated by ultrasound.
C.A.T. SCAN
The centre sections show a single insulinoma in the tail (left), and anothel in the
body of the pancreas (right) - following contrast enhancement of the C.T. scan.
ANGIOGRAPHY
The lower two sections demonstrate the requirement for subtraction technique
to be applied to angiography in the unsubtracted Glms. The insulinoma is totally
obscured by the spinal bone density on the standard engiographic view (right),
whereas it is clearly indicated by subtraction (left).
27morbidity. One tumour was intimately related to the common bile dust which
was damaged during exploration; this was not recognized and lead to a subhepatic
collection of bile requiring drainage subsequently. In two other cases a pancreatic
duct was probably damaged, leadipg to fistula formation in one and a pseudocyst
in the other. To minimise complications we now routinely use a hand lens to
inspect the tumour bed for leakage of pancreatic juice: this leakage can be made
more obvious by injection of secretin. When the tumour was located in the neck,
body or tail, surgery was easier; a distal pancreatectomy was performed in seven
patients and a microscopic adenoma was found. One patient with multiple
endocrine adenomatosis had three macroscopic tumours in the body and tail, and
three further tumours were identified microscopically. A "blind" distal pancrea-
tectomy was performed in only one patient in whom a microscopic adenoma
was found.
MEDICAL MANAGEMENT
Streptozotocin was given to two of the patients with malignant tumours (Cases
6 and 14), who have been reported elsewhere 5, 6. One patient was an insulin-
dependent diabetic who developed hypoglycaemia which persisted even after with-
drawal of insulin therapy. He had an islet cell carcinoma with hepatic metastases.
After intravenous streptozotocin he became hyperglycaemic and again required
insulin. He relapsed after one year despite intensive streptozotocin therapy.
Plasma gastrin was also initially elevated at 290-500 ng/l (normal 0-150 ng/l)
with associated acid hypersecretion, and these values also fell to normal after
streptozotocin. The other patient survived for four years, eventually dying from
cachexia and renal tubular acidosis, which was most probably caused by the drug.
A short course of diazoxide has been successful in maintaining a normal plasma
glucose in case 16, where a large hepatic metastasis remained in situ: It is
uncertain whether this lesion is still truly functioning and both glucose and
insulin values have now remained normal for over a year without further therapy.
Only one patient (Case 15) could be considered to have multiple endocrine
adenomatosis, on the basis of multiple islet cell adenomas and hyperparathy-
roidism. Cells within the islet cell adenoma stained positively for pancreatic
polypeptide. Her father had both a pituitary chromophobe adenoma and a
parathyroid adenoma, and a paternal uncle is known to be panhypopituitary.
Follow-up has varied from one to 18 years. Four patients have died. Case 3,
W.B., died 6 years post-operatively from a cerebrovascular accident. Case 6,
L.I'A., and Case 14, L.M., died 4 and one years respectively after their diagnostic
laparotomies from malignant tumour metastases, although hypoglycaemia had
been effectively treated and the cause of death was ultimate cachexia. Case 7,
M.R., died of heart failure 7 years post-operatively.
In 11 patients a recent value of plasma glucose and insulin was available at
review in 1979. Plasma glucose (random, mid-afternoon) varied from 4.1 to 9.0
mmol/l, and plasma insulin from 2.0 to 32.5 mu/l.
28DISCUSSION
Insulinomas are uncommon and present in widely differing ways 3, 7, 8, 9. The
present series is typical of experience elsewhere in the high proportion of cases
presenting with neurological and psychiatric symptoms. Stefanini et al 8 in a
world-wide literature review of 1067 cases which included 9 of this series, reported
neuropsychiatric complaints in 92 per cent of cases. Other presentations include
gastroenterological symptoms and the generalised features of malignancy.
Since symptoms are intermittent and presenting complaints variable, !ong
delays can occur before the correct diagnosis is made 7, 9. The present study
clearly indicates that awareness of the modes of presentation by doctors in widely
differing fields is the vital step in diagnosis. Subsequent proof of diagnosis has
become easier now that plasma insulin measurements are readily available. This
has simplified many of the tests which were previously advocated 7, 1O. The
present series shows that the plasma glucose and insulin results obtained in early
morning specimens (at least 3), and if necessary during a relatively short further
fast, allowed the diagnosis to be made biochemically in all cases where this
combination was used. The prolonged glucose tolerance test was also useful in
our series but others have pointed out the unreliability of the test 9, ". Currently,
we investigate by collecting a series of early morning fasting plasma glucose and
insulin specimens, the last of which is followed by a prolonged glucose tolerance
test over 6 hours. On the next day, if hypoglycaemia has not been demonstrated,
a prolonged fast is commenced with blood samples being taken every 6 hours for
insulin and glucose measurements. The fast should be stopped after 2 days. During
similar procedures each of our patients had, at some stage, unequivocal hypo-
glycaemia with a clearly raised plasma insulin; these findings agree closely with
those reported in the series of Service et al 9, Scholz et al 12 and Clark et al 1
A more frequent problem is encountered where indefinite symptoms might
possibly be due to hypoglycaemia, but where a low plasma glucose has never been
clearly demonstrated. We have not found any patient with an insulinoma who did
not show unequivocal hypoglycaemia during early morning sampling, a prolonged
oral GTT or during prolonged fasting up to 36 hours. The patient with the smallest
lesion (case 13) clearly demonstrated inappropriate hyperinsulinism on early
morning fasting measurements, but required up to 36 hours continuous fasting
to produce symptomatic hypoglycaemia. More complex tests to provoke insulin
secretion are unnecessary to exclude true insulin-secreting adenomas.
After the biochemical diagnosis had been established selective arteriography
was impressive in localization of the tumour. Before this technique was introduced
and adopted by Olsson 14 in 1963, tumours were found only by observation or
palpation of the pancreas at operation. In our series a tumour as small as 2 cm
in diameter has been visualized; others have claimed to see tumours as small as
0.5 cm 8 There has been one false negative and one false positive arteriogram
(86% success rate). Others have reported rather more false negatives, particularly
when the lesion is in the tail of the pancreas 8, 15-18. Our detailed technique has
been given, as we feel that it is of considerable importance in enhancing the
usefulness of the test; without subtraction tumours occurring in areas overlain
by gas or over the spine or ribs may easily be missed.
29Successful surgery requires accurate localization and adequate exposure. Even
after reliable localization it is advisable to explore the whole pancreas in every
case as the tumour may be multiple or the localization faulty. Though a vertical
incision may be adequate, we have generally preferred a long transverse epigastric
incision. When the tumour is in the head of the pancreas, local excision is safer
than pancreatico-duodenectomy 8; local resection was performed in 7 cases with-
out the mortality reported elsewhere 8 but with considerable short-term morbidity.
When the tumour was located in the neck, body or tail, distal pancreatectomy
was performed in 7 patients. (One early patient underwent a blind distal pancrea-
tectomy, a procedure which we no longer advocate). In circumstances such as
these where no tumour is seen at laparotomy, distal pancreatectomy removes
only about one third of insulinomas 8, 19. In these circumstances intraoperative
catheterization of the splenic and portal veins may be indicated in an attempt
to localize the site of insulin secretion 20, 21.
In the present series, we have seen no recurrences after removal of a benign
tumour. The incidence of malignancy (13%) is in keeping with that described
elsewhere 8, . In a number of cases local invasion was reported histologically,
but these cases have not developed either recurrent hypoglycaemia or other
sequelae of malignant disease. When metastases were present streptozotocin
therapy was of considerable short-term help, although vomiting was a major
problem and one patient (5) developed severe renal tubular acidosis after 4 years
therapy, a complication which has also been reported by other workers 22,
23 24
We conclude that the basic methods of diagnosis of insulinoma have not
changed since radioimmunoassays for insulin became available, and remain based
on the simple demonstration of hypoglycaemia with inappropriate hyperinsul-
inism. A team approach to management in a specialized centre is strongly
advocated; we have shown that arteriography is helpful in localization while
skilled surgery by one team reduces morbidity and mortality. Although the out-
come for patients with metastases was poor, in cases with histologically benign
insulinomas only one recurrence of hypoglycaemia was seen.
We are grateful to Dr. J. S. Logan for his permission to report Case 5. The other patients
were all at some time under the care of the Metabolic Unit. We are grateful to numerous
colleagues for referring patients and for help and consultation during their management.
ADDENDUM
1. J.D. Case 12 died in 1980 from intestinal obstruction associated with recurrent
hypoglycaemia. Autopsy at another hospital did not reveal any evidence of
residual islet cell tumour in the pancreas or elsewhere, but the available
biochemical evidence suggests that there must have been some recurrence.
J.H. Case 8 has developed recurrent hypoglycaemia with inappropriate hyper-
30insulinism in 1981, and liver scans show multiple hepatic secondaries. Review
of the original histology in both cases 8 and 12 does not give any indication that
either might originally have been recognisable as potentially metastatic.
2. Since writing this paper a further patient with an islet cell tumour in the
head of the pancreas has been diagnosed and the lesion successfully removed.
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